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17-AAG = 17-allylamino, 17-demethoxygeldanamycin; CHIP = carboxyl terminus of Hsc70-interacting protein; CIN85 = Cbl interacting protein of
85 kDa; CSF-1 = colony stimulating factor-1; E3 = ubiquitin protein ligase; EGFR = epidermal growth factor receptor; Hsp = heat shock protein;
PTB = phosphotyrosine binding; SH = Src homology domain; TKI = tyrosine kinase inhibitor.
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Introduction
Inappropriate activity of growth factor receptors such as
the epidermal growth factor receptor (EGFR) family, which
comprises EGFR, ErbB-2/Her2/Neu, ErbB-3/Her3, and
ErbB-4/Her4, is associated with the development of a
wide variety of human cancers, including breast cancer
[1]. An understanding of the mechanisms that negatively
regulate growth factor signaling, and characterization of
the function of such negative regulators in both normal
and transformed cells can lead to identification of thera-
peutic targets for treatment of human cancers. Indeed,
there are data to suggest that some existing therapies may
act, at least in part, to enhance such negative regulatory
mechanisms (although they were not developed specifi-
cally to enhance receptor degradation). In the present
review, the role of ubiquitination in the negative regulation
of growth factor receptor signaling is discussed. Much of
the information regarding downregulation of growth factor
receptors has been generated by studies of EGFR.
However, the basic mechanisms described for EGFR are
likely to regulate signaling by many growth factor recep-
tors. Evidence is also presented that suggests that tumor
cells may subvert the ubiquitin-based negative regulation
of growth factor receptors. In addition, therapeutic options
are discussed.
Ubiquitination and the regulation of cellular
proteins
Ubiquitin is a highly conserved, 76-amino-acid protein that
can be covalently conjugated to the lysine residues on a
wide assortment of proteins and thus regulate their func-
tion (for review [2]). Ubiquitination of proteins occurs via
sequential activation and conjugation of ubiquitin to target
proteins by the ubiquitin-activating enzyme, a ubiquitin-
conjugating enzyme, and a ubiquitin protein ligase (E3)
[2]. The E3 protein confers specificity to the ubiquitination
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process and directs the conjugation of ubiquitin to one or
more lysines of the specific target protein. Ubiquitin can
form multi-ubiquitin chains, in which the first ubiquitin is
attached via an isopeptide linkage to a lysine of the target
protein and the subsequent ubiquitin molecules are conju-
gated to lysine 48 of the preceding ubiquitin molecule.
Such lysine-48-linked multi-ubiquitin chains of four or
more ubiquitin molecules can efficiently target proteins for
degradation by the proteasome. Proteins may also be
mono-ubiquitinated, or have di-ubiquitinated or multi-ubiq-
uitinated chains that are linked via lysine 63 on the ubiqui-
tin molecule. Rather than target proteins for proteasomal
degradation, the latter ubiquitin modifications serve to reg-
ulate protein trafficking or function [2,3]. Endocytosis and
targeting of proteins to lysosomal degradation can be reg-
ulated by mono-ubiquitination or lysine-63-linked ubiquitin
chains [2,3]. Thus, ubiquitination can serve either to target
proteins to proteasomes or to lysosomes for degradation
[4–6].
There are two ubiquitin-dependent mechanisms of growth
factor receptor degradation: ligand-dependent degrada-
tion (discussed below) and ligand-independent degrada-
tion (discussed under Growth factor receptor degradation
as cancer therapy) (Fig. 1). Both mechanisms have proven
accessible to therapeutic interventions.
Ligand-dependent growth factor receptor
downregulation
Upon ligand activation of many receptor tyrosine kinases
such as the EGFR there is a rapid decrease in the cell
surface number of the receptors and an eventual decrease
in the cellular content of activated receptors – a process
known as ‘downregulation’ [5]. This process can be
divided into two distinct phases: internalization of the
membrane receptor and degradation of the internalized
receptor.
In nontransformed cells, inactive growth factor receptors
may be concentrated in specific membrane regions known
as caveolae [7]. Caveolae are small invaginations in the
cell membrane that are enriched with caveolins, spingo-
lipid, and cholesterol. Caveolae may serve to spatially
organize signaling molecules that interact with the recep-
tors upon activation. In transformed cells that overexpress
growth factor receptors, however, the receptors may not
be concentrated in caveolae. This has been demonstrated
for the EGFR in A431 cells [8], but no data exist regarding
other members of the EGFR family. Upon ligand-mediated
activation of the growth factor receptors, the receptors
exit the calveolae and localize to another type of specific
membrane region known as the clathrin-coated pit.
Clathrin-coated pits are membrane invaginations coated
by a lattice of clathrin proteins, and these pits are the
major sites of endocytosis of activated membrane recep-
tors [5,9]. These invaginations pinch off to form clathrin-
coated vesicles, thus internalizing the membrane proteins
localized within these clathrin-coated pits. Specific amino
acid sequences within membrane protein cytoplasmic tails
target proteins to the clathrin-coated pits, where they
undergo endocytosis [5,9].
On the basis of recent publications, a mechanism for inter-
nalization of EGFR can be described (Fig. 1). Upon activa-
tion of the EGFR by ligand, Cbl proteins are recruited
rapidly to the EGFR and mediate ubiquitination of the
EGFR [10]. Cbl proteins are a family of proteins that are
conserved throughout metazoans and have E3 activity,
and which can also serve as adaptor proteins [10]. All Cbl
proteins contain an amino-terminal phosphotyrosine
binding (PTB) domain and a C3HC4 RING finger. The
RING finger is essential for the E3 activity of Cbl proteins
[10]. Cbl proteins can bind to the EGFR via two types of
interactions. They can interact directly via their PTB
domain with a phosphorylated tyrosine in the EGFR cyto-
plasmic tail (Y1045) or they can interact indirectly via
binding to Grb2 [11,12]. Upon EGFR activation, Cbl pro-
teins are tyrosine phosphorylated by Src kinases [13].
However, phosphorylation of Cbl proteins is not required
for their interaction with EGFR. Phosphorylation of Cbl
proteins does enhance binding to Grb2 (which can bind
via both SH2 and SH3 interactions with Cbl proteins). In
addition, phosphorylation of Cbl proteins enhances inter-
action with another adaptor protein, namely Cbl interact-
ing protein of 85 kDa (CIN85) [14,15]. CIN85 contains
three SH3 domains that interact with the carboxyl-terminal
proline-rich domains of Cbl proteins [16–18]. CIN85 in
turn is constitutively associated with endophilins [14,15].
Endophilins have been implicated in the control of clathrin-
mediated endocytosis by binding to regulatory compo-
nents of endocytosis such as dynamin, amphiphysin, and
synoptojanin (for references [14,15]). Thus, binding of Cbl
to the activated EGFR and recruitment of CIN85 couples
EGFR to clathrin-mediated endocytosis [14].
The role of ubiquitination in the endocytosis of EGFR has
not been clearly demonstrated. Cbl proteins may mediate
endocytosis by serving as adaptor proteins as outlined
above. However, a number of lines of evidence suggest
that ubiquitination of the EGFR probably plays a role in
endocytosis of the receptor. First, it has been established
that ubiquitination is required for internalization of a
number of membrane receptors in yeast [3]. Second, the
growth hormone receptor, like EGFR, undergoes ligand-
induced ubiquitination and downregulation, and inhibition
of ubiquitination prevents internalization of the growth
hormone receptor [19–21]. Third, Cbl association with
and ubiquitination of EGFR occur at the cell membrane
before internalization [22]. Finally, Eps15, an EGFR tyro-
sine kinase substrate that associates with the clathrin
adaptor protein AP-2, has recently been shown to bind to
ubiquitinated proteins via a ubiquitin-interacting motif10
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[23,24]. Inhibition of Eps15 function prevents EGFR inter-
nalization [24]. Eps15, therefore, could bind to the ubiqui-
tinated EGFR via this ubiquitin-interacting motif and serve
to direct EGFR to the clathrin-coated pit. Both Cbl pro-
teins and Eps15 appear to have overlapping roles in tar-
geting the activated, ubiquitinated EGFR for
clathrin-mediated endocytosis. Whether these are part of
one mechanism or represent alternative pathways remains
to be determined.
Upon internalization, EGFR can be found in a vesicular
structure near the cell periphery known as the early endo-
some [5]. From the early endosome, the growth factor
receptor can either be recycled to the plasma membrane or
it can be degraded. The decision to recycle or degrade
appears to be regulated in part by the E3 activity of Cbl
proteins. Ubiquitination of the EGFR increases its traffick-
ing to the multivesicular body and eventually to the lyso-
some, where it is degraded [5,25]. Cbl proteins have been
Figure 1
Ubiquitin (Ub)-mediated pathways of growth factor receptor (GFR) downregulation. There are two ubiquitin-mediated pathways of GFR
degradation: ligand-dependent degradation (shown to the right) and ligand-independent degradation (shown to the left). Ligand-dependent
degradation: upon ligand-induced activation of the mature GFR, Cbl proteins are recruited to the GFR and mediate ubiquitination, internalization,
and degradation of the GFR (see text for details). Cin85, endophillins (End), and Eps 15 are involved in the internalization of the GFR. Regulatory
proteins include protein kinase C (PKC) and Sprouty (spty). Ligand-independent degradation: a complex of protein chaperones (the stabilizing
chaperone complex), including heat shock protein (Hsp)90, associates with both the nascent GFR in the endoplasmic reticulum and the mature
GFR on the cell membrane and helps stabilize the protein. Drugs such as the benzoquinone ansamycins or tyrosine kinase inhibitor (TKIs) induce a
change in the chaperone complex composition to one that favors degradation of the bound proteins (the degrading chaperone complex). The
altered chaperone complex recruits an E3 ligase, which ubiquitinates the bound proteins, which in turn leads to their degradation by the
proteasome (see text for details). E3 proteins are shown in green. The red color indicates current or potential agents that might enhance receptor
degradation and thus be of clinical utility as treatment for cancer. E2, ubiquitin conjugation enzyme.11
shown to enhance ligand-induced degradation of EGFR.
Recent work has further demonstrated that the Cbl pro-
teins and other proteins within the active signaling
complex, such as Grb2 and Shc, are coordinately
degraded [26]. Thus Cbl proteins appear to play a second
role in determining the sorting to the degradation pathway.
This enhanced degradation of activated EGFR requires
tyrosine kinase activity by the EGFR, interaction of Cbl pro-
teins with phosphorylated tyrosines in the carboxyl-terminal
tail of EGFR, and the E3 activity of Cbl proteins [12].
Although most data suggest that the EGFR is degraded in
the lysosome, experiments using lysosome or proteasome
inhibitors have demonstrated that both block degradation
of the receptor as well as the complex of proteins
degraded along with the receptor [26,27]. The relation-
ship between ubiquitination of plasma membrane proteins
and their internalization, trafficking, and degradation is
complex. In yeast, there are membrane proteins that are
targeted for degradation in the vacuole by ubiquitination
but whose degradation is independent of proteasome
function [3,28]. In mammalian cells, ligand-induced inter-
nalization and degradation of growth hormone receptor
requires an intact ubiquitinating system, intact proteasome
function, and intact lysosome function [19–21]. However,
ubiquitination of growth hormone receptor itself is not
required for degradation, but inhibition of proteasome
function prevents internalization and degradation of the
receptor [21]. Similar to the growth hormone receptor,
degradation of EGFR is blocked by both proteasome and
lysosome inhibitors [26,27,29]. The role of the protea-
some in EGFR degradation, while implicated by inhibitor
studies, is unclear. One possibility is that proteasome
inhibitors may inhibit lysosomal degradation of the EGFR
by depleting pools of free ubiquitin. This could inhibit Cbl-
mediated ubiquitination of the EGFR and prevent traffick-
ing of the ubiquitinated EGFR complex to the lysosomal
compartment. In yeast, depletion of free ubiquitin has been
shown to inhibit both proteasomal and lysosomal degrada-
tion [30]. However, although degradation of the EGFR
complex is blocked by proteasome inhibitors, EGF still
induces polyubiquitination of EGFR in the presence and
absence of proteasome inhibitors [25]. This is consistent
with a role for the proteasome in degradation of the EGFR
complex. Thus, it is possible that the entire EGFR signal-
ing complex traffics to the lysosome, where it is coordi-
nately degraded by both lysosomal and proteasomal
mechanisms. Alternatively, proteasomal degradation of
regulatory proteins may be necessary for trafficking of the
EGFR to the lysosome.
Many other proteins are known to play a role in downregu-
lation of growth factor receptors [5]. For example, protein
kinase C has been shown to phosphorylate EGFR on thre-
onine 654, resulting in decreased ligand-induced ubiquiti-
nation, decreased degradation, and increased recycling of
EGFR (Fig. 1) [31]. The precise mechanism by which
protein kinase C mediated phosphorylation of EGFR
changes the fate of the internalized receptor from destruc-
tion to recycling remains to be determined. Another
recently described family of regulatory molecules is the
human Sprouty protein family. In studies in human cells,
Sprouty proteins were shown to enhance EGFR signaling
by sequestering Cbl proteins, thus preventing Cbl-medi-
ated ubiquitination and degradation (Fig. 1) [32].
Growth factor receptor downregulation and
carcinogenesis
As noted above, the Cbl proteins are critical regulators of
receptor downregulation. Mutant forms of c-Cbl that act
as oncogenes have been identified. The v-Cbl oncogene,
the first Cbl protein identified, is the transforming gene of
the Cas-NS-1 murine retrovirus, which causes pre-B-cell
lymphomas and myeloid leukemias in mice and which
transforms NIH 3T3 cells [10]. v-Cbl is a truncated version
of its cellular homologue c-Cbl. v-Cbl retains only the
amino-terminal PTB domain and acts as a dominant nega-
tive inhibitor of c-Cbl-induced receptor downregulation
[27]. Two other transforming forms of c-Cbl have been
identified in cell lines derived from carcinogen-induced
murine lymphomas, namely 70Z Cbl and p95Cbl [33,34].
Both of those transforming Cbl proteins have deletions
that encompass part of the linker region between the PTB
domain and the RING finger and some or all of the RING
finger. The RING finger is essential for E3 activity, and
these mutant proteins cannot function as an E3. Thus, the
likely mechanism of transformation by these variants of c-
Cbl is inhibition of downregulation of activated growth
factor receptors [10]. In human gastrointestinal tumors
with microsatellite instability, one study described expan-
sion of a trinucleotide repeat in the c-Cbl gene in 1 out of
11 tumors analyzed [35]. The functional significance of
this mutation has not been characterized, and transform-
ing forms of the other mammalian Cbl proteins (Cbl-b and
Cbl-c) have not been described in either human or murine
tumors.
Two recent reports have identified oncogenic mutations in
growth factor receptors that eliminate the binding site for
Cbl proteins. The Met receptor is the receptor for hepato-
cyte growth factor and is ubiquitinated and downregulated
by c-Cbl [36]. The oncogenic TPR-Met receptor was gen-
erated by a carcinogen-induced chromosomal transloca-
tion in a nontumorigenic human sarcoma cell line. This
oncogenic receptor lacks the tyrosine binding site for Cbl
[36]. TPR-Met is constitutively active but it is not ubiquiti-
nated and fails to bind c-Cbl. This suggests that the failure
to downregulate the receptor contributes to the transform-
ing ability of TPR-Met. Indeed, mutation of only the Cbl-
binding site of the Met receptor is sufficient to promote
ligand-independent oncogenic activation of the Met recep-
tor [36].
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The v-Fms oncogene is a mutated version of the feline
colony stimulating factor-1 (CSF-1) receptor. c-Cbl has
been shown to ubiquitinate the CSF-1 receptor upon
ligand activation [37]. Interestingly, the v-Fms oncogene
has deleted a carboxyl-terminal tyrosine (Y977), which is
the binding site for c-Cbl [37]. As a result, c-Cbl does not
ubiquitinate v-Fms or inhibit transformation by v-Fms. Rein-
troduction of the Cbl-binding site into v-Fms reduces the
transforming potency of v-Fms, and coexpression of c-Cbl
inhibited transformation by this form of the v-Fms onco-
gene [37]. Mutation of the equivalent tyrosine in the
human CSF-1 receptor enhanced the ability of the recep-
tor to transform fibroblasts [38]. Point mutations in the
Cbl-binding site have been found in children with sec-
ondary myelodysplasia and acute myeloid leukemia
[39,40].
Mutations that interfere with downregulation of activated
growth factor receptors and that result in malignant trans-
formation demonstrate the importance of receptor down-
regulation in normal homeostasis. No mutations in proteins
involved in receptor downregulation have yet been
described in human epithelial malignancies, including
breast cancer. However, the amplification and overexpres-
sion of ErbB-2 in a variety of human malignancies may, in
fact, affect downregulation of EGFR. Of the receptors in
the EGFR family, only EGFR undergoes ligand-induced
downregulation [41]. ErbB-2 does not have a ligand that
activates it. Instead, it is activated via heterodimerization
with ligand-bound EGFR, ErbB-3, or ErbB-4 [42]. Homo-
dimerization of EGFR by epidermal growth factor results in
EGFR downregulation [41]. However, heterodimerization
of ErbB-2 with the activated EGFR prevents binding of
Cbl proteins and inhibits downregulation of EGFR [43].
This results in more potent signaling by EGFR/ErbB-2 het-
erodimers as compared with EGFR homodimers [43].
Amplification of ErbB-2, then, would be predicted to
increase the fraction of EGFR in heterodimers upon acti-
vation, decrease the degradation of the activated EGFR,
and increase the potency of the signal upon ligand
binding. Further investigation of receptor downregulation
in human breast cancer is warranted based on observa-
tions such as these.
Growth factor receptor degradation as cancer
therapy
Therapies that enhance growth factor receptor downregu-
lation have been tested for activity in human cancers
(although none were originally developed to target down-
regulation).
Monoclonal antibodies that target cell surface receptors
have been developed to inhibit receptor function, either by
blocking activity or by inducing an immune response to the
cells bearing those receptors. In vitro studies have shown
that a variety of anti-ErbB-2 antibodies can inhibit cell pro-
liferation and block the growth of tumor xenografts of cells
that overexpress ErbB-2 [44,45]. Trastuzumab (Herceptin®,
Genentech, South San Francisco, CA, USA) – the human-
ized version of one of these antibodies – has clinical activ-
ity alone and in combination with chemotherapy in
metastatic breast cancer, and has been approved for use
in patients whose tumors overexpress ErbB-2 [46,47].
ErbB-2 overexpressing breast and ovarian cells exposed
to Trastuzumab have marked downregulation of ErbB-2,
resulting in a selective decrease in activation of the pro-
survival kinase AKT [48]. Downregulation of the ErbB-2
receptor and AKT activity has been shown to increase
sensitivity of the cells to apoptosis induced by the tumor
necrosis factor family of ligands [48,49]. Recent work has
shown that the downregulation induced by these antibod-
ies involves recruitment of Cbl proteins to and subsequent
ubiquitination of ErbB-2 [45]. Mechanistically, these anti-
bodies are weak agonists and presumably induce activa-
tion of ErbB-2 by homodimerization [50], thus exposing
the Cbl-binding sites in a manner similar to homodimeriza-
tion of EGFR by epidermal growth factor. This in turn
results in ubiquitination and downregulation [45]. In con-
trast, the normal mechanism of activation of ErbB-2 by
heterodimerization with one of the other family members
results in masking of the Cbl-binding sites [43]. It is likely
that the synergistic interaction between Trastuzumab and
chemotherapy in patients is due in part to enhanced
receptor downregulation.
The ligand-independent mechanism of receptor degrada-
tion was discovered in the course of studying the mecha-
nism of action of the benzoquinone ansamycins (e.g.
herbimycin A; geldanamycin; and 17-allylamino, 17-
demethoxygeldanamycin [17-AAG]) (Fig. 1). This class of
drugs was initially identified as inhibitors of the Src tyro-
sine kinase [51,52]. Subsequent studies revealed that
they had no direct effect on tyrosine kinase activity but
instead enhanced degradation of a wide range of proteins,
including EGFR and ErbB-2 [51,52]. These drugs target
the molecular chaperones Hsp90 and Grp94 [51,52]. The
chaperone proteins are involved in the stabilization and
folding, trafficking, and degradation of proteins. The drugs
bind to these chaperone proteins and force the chaperone
complex to adopt a protein destabilizing conformation.
This results in the ubiquitination and degradation of the
proteins that bind to the chaperones [51,52]. These drugs
appear to be able to enhance degradation of both the
newly synthesized receptors that have not yet reached the
plasma membrane and the mature plasma membrane
receptors [53–56].
The mechanism of degradation of membrane receptors by
the benzoquinone ansamycins is distinct from ligand-
induced degradation. In contrast to the lysosomal mecha-
nism of ligand-induced degradation described above,
ligand-independent degradation is mediated by the pro-
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teasome [51,57]. Drug-induced degradation of membrane
receptors is independent of kinase activity of the growth
factor receptors but requires the presence of the kinase
domain [56]. The chaperone complex associates with the
membrane receptors via the kinase domain of the recep-
tor, and mutations that inactivate the kinase appear to
enhance the association of the chaperones with growth
factor receptors [56,58]. Drug-induced degradation is
unaffected by deletion of amino acid sequences carboxyl-
terminal to the kinase domain [56]. In contrast, ligand-
dependent degradation of growth factor receptors
requires activation of kinase activity (mutations that
abolish kinase activity block downregulation) and requires
phosphorylation of tyrosines in the carboxyl-terminal tails
of the receptors (which act as a binding site for Cbl pro-
teins) [12,45,59]. In addition, Cbl proteins do not appear
to mediate ubiquitination of proteins induced by the ben-
zoquinone ansamycins. A unique E3 (the U-box protein “
carboxyl terminus of Hsc70-interacting protein” or CHIP)
has been shown to be a chaperone-dependent E3-ligase
for several proteins degraded by the drugs (reviewed in
[60]). Recent work suggests that CHIP also mediates the
drug-induced polyubiquitination of ErbB-2 (Y Yarden, per-
sonal communication). Phase I clinical trials are currently
underway to explore the use of 17-AAG in cancer
patients.
Recent observations suggest that the ligand-independent
mechanism of receptor degradation may be induced by
small molecule tyrosine kinase inhibitors (TKIs; Fig. 1)
[58]. Geldanamycin was observed to enhance ubiquitina-
tion and degradation of a kinase dead mutant of EGFR but
not of wild-type EGFR. This observation led those investi-
gators to test whether TKIs, which inactivate the kinase
biochemically, would have a similar effect to gel-
danamycin. Subsequent studies demonstrated that an irre-
versible TKI (CI-1033) enhanced endocytosis,
ubiquitination, and proteasomal degradation of mature
ErbB-2 molecules. In addition, the TKI enhanced degrada-
tion of nascent ErbB-2 molecules. Mechanistically, it
appears that TKIs perturb the structure of the chaperone
protein complex associated with ErbB-2. Like the benzo-
quinone ansamycins, TKIs alter the composition and struc-
ture of the chaperone complex to one that favors
ubiquitination and degradation of the associated ErbB-2.
Thus, the ligand-independent ubiquitination and degrada-
tion of membrane receptors may be relevant to the clinical
efficacy of TKIs.
The efficacy of agents that affect growth factor receptor
downregulation both in experimental models (for
Trastuzumab, 17-AAG, and TKIs) and in clinical trials (for
Trastuzumab) provides evidence that the development of
other agents designed to target downregulation of growth
factor receptors is warranted. Obvious directions would
be to expand upon the examples above. The development
of antibodies and/or drugs that bind to the extracellular
domains of growth factor receptors and induce ligand-
dependent downregulation can be envisioned for a variety
of receptors that are known to be important in the patho-
genesis of cancer. Another approach would be to develop
small molecules that enhance the ligand-activated down-
regulation pathway. One possible approach would be to
identify inhibitors of protein kinase C, because this would
potentially enhance sorting of the receptors to the degra-
dation pathway. Another approach would be to inhibit the
function of proteins such as Sprouty, which negatively reg-
ulate Cbl function. Similarly, additional drugs that inhibit
the function of Hsp90, Grp94, and other chaperone pro-
teins may have clinical efficacy. As more is learned about
the downregulation pathway, additional targets should
become apparent.
Of note is that different receptors appear more suscepti-
ble to either ligand-dependent or ligand-independent
degradation. For example, the EGFR is downregulated to
a greater degree than is ErbB-2, ErbB-3, or ErbB-4 in
response to ligand activation, but it is relatively insensitive
to downregulation induced by benzoquinone ansamycins
[41,58]. In contrast, ErbB-2 is more sensitive than the
EGFR to downregulation induced by benzoquinone
ansamycins or the TKIs [56,58]. The development of
effective agents to induce downregulation will depend on
a solid understanding of the mechanisms relevant to each
target receptor.
Another therapeutic approach that is dependent on recep-
tor downregulation for its efficacy is the use of recombi-
nant toxins (for review [61,62]). In this approach, a toxin
such as Pseudomonas exotoxin A lacking its cell-binding
domain is targeted to specific cancer cells by conjugation
to either a growth factor or an antibody directed at a cell
surface receptor [61,62]. Normally, these toxins bind to
cell surface receptors and are internalized via clathrin-
coated pits into the endosomal compartment, where they
are processed and released into the cytosol [61,62]. For
the recombinant toxin conjugates to be active, they must
be efficiently internalized by the cell surface protein to
which they are targeted by the fusion partner. Recombi-
nant toxins targeted to growth factor receptors of the
EGFR family have been used in experimental models and
in phase I clinical trials [63–67]. The importance of inter-
nalization was confirmed in studies of a betacellulin–
Pseudomonas toxin fusion protein [65]. This recombinant
toxin binds to and activates both EGFR and ErbB-4, but is
efficiently internalized only upon binding to EGFR. The effi-
cacy of the toxin is much greater in cells that express
EGFR as compared with cells that express ErbB-4 [65].
The addition of agents that induce internalization of the
growth factor receptor either through the ligand-depen-
dent or the ligand-independent mechanism may enhance
the efficacy of the recombinant toxins.
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Conclusion
The past several years have seen a dramatic improvement
in our understanding of pathways that control growth factor
receptor downregulation. Concurrent with this improved
understanding is an appreciation that genetic alterations in
cancer cells can directly affect receptor downregulation
and that this may contribute to the pathogenesis of cancer.
Finally, agents that alter downregulation of growth factor
receptors have shown promise as therapies for cancer.
Thus, novel agents designed specifically to enhance
growth factor receptor downregulation may provide a
useful class of agents in the treatment of cancer.
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